Want to see IN:HIKAL full AI Analyst Report?
HIKAL Stock Chart & Stats
₹217.20
₹4.58(2.11%)
At close: 4:00 PM EDT
₹217.20
₹4.58(2.11%)
Day’s Range― - ―
52-Week Range₹145.95 - ₹260.80
Previous CloseN/A
Volume197.35K
Average Volume (3M)129.44K
Market Cap
₹27.92B
Enterprise Value₹24.83B
Total Cash (Recent Filing)₹138.00M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.27%
Share Statistics
EPS (TTM)-2.74
Shares Outstanding123,300,750
10 Day Avg. Volume54,409
30 Day Avg. Volume129,437
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.51
Price to Sales (P/S)1.06
P/FCF Ratio20.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.9
Revenue Forecast (FY)₹19.00B
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationPositive operating and free cash flow show that Hikal continues converting business activity into cash despite a loss-making year. This supports ongoing operations and investment capacity, while providing some resilience as management works to restore profitability over the coming quarters.
Improving LeverageDebt reduction and a sizable equity base improve Hikal’s financial flexibility and reduce balance-sheet pressure. A more manageable leverage position can help the company fund manufacturing and development needs while giving it greater capacity to withstand earnings volatility.
Diversified Specialty Chemicals ModelServing both pharmaceutical and agrochemical value chains gives Hikal multiple end markets and embeds its process chemistry and manufacturing capabilities in customer supply programs. This B2B model can support recurring demand when products remain approved and commercially relevant.
Bears Say
Recent Loss-making ProfitabilityThe swing to a net loss materially weakens earnings quality and reduces confidence in near-term self-funded growth. Unless margins recover or operating costs moderate, the deterioration could constrain reinvestment, weaken returns on the asset base, and increase sensitivity to demand changes.
Uneven Revenue MomentumInconsistent and recently declining revenue indicates that customer demand or product volumes have not yet established a dependable growth trajectory. Persistent unevenness would make capacity planning harder and limit operating leverage, especially while the company is trying to recover profitability.
Volatile Cash ConversionAlthough cash flow remained positive in 2026, the sharp year-over-year decline and prior negative period show that conversion can fluctuate significantly. Such volatility may complicate funding for capital spending and development programs, particularly if weak earnings persist.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹145.95 and its highest was ₹260.80 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹27.92B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Nov 18, 2026 which is in 40 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on Aug 06, 2026. The company reported -₹1.3 earnings per share for the quarter.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.4 which represents an annual dividend yield of 0.27%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of -₹1.3 in its last earnings report. Following the earnings report the stock price went down -4.222%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Rossari Biotech Ltd
―
Solara Active Pharma Sciences Ltd.
―
Supriya Lifescience Limited
―
Wockhardt Limited
―